Computational Analysis of Microrna Profiles and their Target Genes Involved in Multidrug Resistance of Breast Cancer Cell


Article Preview

Multidrug resistance remains a major clinical obstacle to successful treatment of breast cancer and leads to poor prognosis for the patients. Recently studies have shown that microRNAs play an important role in breast cancer cell resistance to chemotherapeutic agents. In this study, microRNA expression profiles of MCF-7/AdrVp and MCF-7 were analyzed using microarray. Gene Ontology and pathways mapping tools were employed to analysis systemically the biological processes and signaling pathways affected by differential expression microRNAs. The results indicated that breast cancer cell resistant to chemotherapy was associated with a group of microRNAs. Gene Ontology and pathway mapping are valid and effective approach to analysis the function of microRNAs and the results could be a guideline for further investigation.



Edited by:

J.L. Zhong






G. Q. Chen and Z. W. Zhao, "Computational Analysis of Microrna Profiles and their Target Genes Involved in Multidrug Resistance of Breast Cancer Cell", Advanced Materials Research, Vol. 345, pp. 304-309, 2012

Online since:

September 2011




[1] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell 2004; 116(2): 281-97.

[2] Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs[J]. Nature 2005; 433(7027): 769-73.

DOI: 10.1038/nature03315

[3] Croce CM, Calin GA. miRNAs, cancer, and stem cell division[J]. Cell 2005; 122(1): 6-7.

[4] Gusev Y. Computational methods for analysis of cellular functions and pathways collectively targeted by differentially expressed microRNA[J]. Methods 2008; 44(1): 61-72.

DOI: 10.1016/j.ymeth.2007.10.005

[5] Huang da W, Sherman BT, Tan Q, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists[J]. Nucleic Acids Res 2007; 35(Web Server issue): W169-75.

DOI: 10.1093/nar/gkm415

[6] Draghici S, Khatri P, Tarca AL, et al. A systems biology approach for pathway level analysis[J]. Genome Res 2007; 17(10): 1537-45.

DOI: 10.1101/gr.6202607

[7] Nam S, Kim B, Shin S, Lee S. miRGator: an integrated system for functional annotation of microRNAs[J]. Nucleic Acids Res 2008; 36(Database issue): D159-64.

DOI: 10.1093/nar/gkm829

[8] Chen YN, Mickley LA, Schwartz AM, et al. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein[J]. J Biol Chem 1990; 265(17): 10073-80.

[9] Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells[J]. Proc Natl Acad Sci U S A 1998; 95(26): 15665-70.

[10] Chédotal A, Kerjan G, Moreau-Fauvarque C. The brain within the tumor: new roles for axon guidance molecules in cancers[J]. Cell Death Differ 2005; 12(8): 1044-56.

DOI: 10.1038/sj.cdd.4401707

[11] Chédotal A. Chemotropic axon guidance molecules in tumorigenesis[J]. Prog Exp Tumor Res 2007; 39: 78-90.

DOI: 10.1159/000100048

[12] Yoo YA, Kim YH, Kim JS, Seo JH. The functional implications of Akt activity and TGF-beta signaling in tamoxifen-resistant breast cancer[J]. Biochim Biophys Acta 2008; 1783(3): 438-47.

DOI: 10.1016/j.bbamcr.2007.12.001

[13] Normanno N, Campiglio M, Maiello MR, et al. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling[J]. Breast Cancer Res Treat 2008; 112(1): 25-33.

DOI: 10.1007/s10549-007-9830-2

[14] Nahta R, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells[J]. Cancer Res 2005; 65(23): 11118-28.

DOI: 10.1158/0008-5472.can-04-3841

[15] Bender LM, Nahta R. Her2 cross talk and therapeutic resistance in breast cancer[J]. Front Biosci 2008; 13: 3906-12.

DOI: 10.2741/2978

[16] Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal[J]. Cancer Sci 2003; 94(1): 15-21.

[17] Wendel HG, Malina A, Zhao Z, et al. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 2006; 66(15): 7639-46.

In order to see related information, you need to Login.